Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Sanofi (SNY) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Sanofi (SNY) over the last 17 years, with Q4 2025 value amounting to 55.87%.

  • Sanofi's EBIT Margin rose 469600.0% to 55.87% in Q4 2025 from the same period last year, while for Dec 2025 it was 11.79%, marking a year-over-year decrease of 69000.0%. This contributed to the annual value of 14.54% for FY2025, which is 31100.0% down from last year.
  • As of Q4 2025, Sanofi's EBIT Margin stood at 55.87%, which was up 469600.0% from 22.84% recorded in Q3 2025.
  • In the past 5 years, Sanofi's EBIT Margin ranged from a high of 99.36% in Q4 2022 and a low of 7.53% during Q2 2025
  • Its 5-year average for EBIT Margin is 25.54%, with a median of 22.33% in 2022.
  • In the last 5 years, Sanofi's EBIT Margin tumbled by -1431000bps in 2021 and then surged by 846100bps in 2022.
  • Over the past 5 years, Sanofi's EBIT Margin (Quarter) stood at 14.75% in 2021, then surged by 574bps to 99.36% in 2022, then plummeted by -82bps to 18.28% in 2023, then crashed by -51bps to 8.91% in 2024, then surged by 527bps to 55.87% in 2025.
  • Its EBIT Margin stands at 55.87% for Q4 2025, versus 22.84% for Q3 2025 and 7.53% for Q2 2025.